Obesity and renovascular disease

American Journal of Physiology - Renal Physiology

Volumn 309, Issue 4, 2015, Pages F273-F279

  Zhang, Xin ^a   Lerman, Lilach O ^a  

^a MAYO CLINIC   (United States)

Author keywords

Adipocyte; Insulin resistance; Microvascula ture; Obesity; Renal artery stenosis; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE; ANGIOGENIC FACTOR; ANGIOPOIETIN 1; CYCLIC AMP DEPENDENT PROTEIN KINASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; INDOMETACIN; INSULIN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTAGLANDIN; PROTEIN TYROSINE PHOSPHATASE 1B; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; ANGIOGENIC PROTEIN;

CARDIOVASCULAR DISEASE; CELL DAMAGE; CELL VIABILITY; ENERGY METABOLISM; FATTY ACID OXIDATION; GLOMERULAR FILTRATION BARRIER; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY ARTERY STENOSIS; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY INJURY; LIPID STORAGE; MICROVASCULATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PREVALENCE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR DISEASE; RENOVASCULAR HYPERTENSION; REVIEW; RISK FACTOR; WEIGHT GAIN; ANIMAL; HEMODYNAMICS; HYPERTENSION, RENOVASCULAR; KIDNEY CIRCULATION; METABOLISM; MICROCIRCULATION; PATHOPHYSIOLOGY; PROGNOSIS; RENAL ARTERY OBSTRUCTION; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; SIGNAL TRANSDUCTION;

ANGIOGENIC PROTEINS; ANIMALS; HEMODYNAMICS; HUMANS; HYPERTENSION, RENOVASCULAR; MICROCIRCULATION; OBESITY; PREVALENCE; PROGNOSIS; RENAL ARTERY OBSTRUCTION; RENAL CIRCULATION; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84939485625     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00547.2014     Document Type: Review

References (86)

1. Armitage JA, Burke SL, Prior LJ, Barzel B, Eikelis N, Lim K, Head GA. Rapid onset of renal sympathetic nerve activation in rabbits fed a high-fat diet. Hypertension 60: 163-171, 2012.
2. Bagby SP. Obesity-initiated metabolic syndrome and the kidney: a recipe for chronic kidney disease? J Am Soc Nephrol 15: 2775-2791, 2004.
3. Belin de Chantemele EJ, Ali MI, Mintz JD, Rainey WE, Tremblay ML, Fulton DJ, Stepp DW. Increasing peripheral insulin sensitivity by protein tyrosine phosphatase 1B deletion improves control of blood pressure in obesity. Hypertension 60: 1273-1279, 2012.
4. Briones AM, Nguyen Dinh Cat A, Callera GE, Yogi A, Burger D, He Y, Correa JW, Gagnon AM, Gomez-Sanchez CE, Gomez-Sanchez EP, Sorisky A, Ooi TC, Ruzicka M, Burns KD, Touyz RM. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 59: 1069-1078, 2012.
5. Buglioni A, Cannone V, Cataliotti A, Sangaralingham SJ, Heublein DM, Scott CG, Bailey KR, Rodeheffer RJ, Dessi-Fulgheri P, Sarzani R, Burnett JC. Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease. Hypertension 65: 45-53, 2015.
6. Butlen D, Vadrot S, Roseau S, Morel F. Insulin receptors along the rat nephron: [125I] insulin binding in microdissected glomeruli and tubules. Pflügers Arch 412: 604-612, 1988.
7. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 117: e510-e526, 2008.
8. Cao R, Brakenhielm E, Wahlestedt C, Thyberg J, Cao Y. Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF. Proc Natl Acad Sci USA 98: 6390-6395, 2001.
9. Cardillo C, Campia U, Iantorno M, Panza JA. Enhanced vascular activity of endogenous endothelin-1 in obese hypertensive patients. Hypertension 43: 36-40, 2004.
10. Carlyle M, Jones OB, Kuo JJ, Hall JE. Chronic cardiovascular and renal actions of leptin: role of adrenergic activity. Hypertension 39: 496-501, 2002.
11. Chade AR. VEGF: potential therapy for renal regeneration. F1000 Med Rep 4: 1, 2012.
12. Chade AR, Zhu X, Mushin OP, Napoli C, Lerman A, Lerman LO. Simvastatin promotes angiogenesis and prevents microvascular remodeling in chronic renal ischemia. FASEB J 20: 1706-1708, 2006.
13. Chagnac A, Herman M, Zingerman B, Erman A, Rozen-Zvi B, Hirsh J, Gafter U. Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption. Nephrol Dial Transplant 23: 3946-3952, 2008.
14. Chagnac A, Weinstein T, Herman M, Hirsh J, Gafter U, Ori Y. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 14: 1480-1486, 2003.
15. Chen J, Muntner P, Hamm LL, Fonseca V, Batuman V, Whelton PK, He J. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol 14: 469-477, 2003.
16. Ciupinska-Kajor M, Hartleb M, Kajor M, Kukla M, Wylezol M, Lange D, Liszka L. Hepatic angiogenesis and fibrosis are common features in morbidly obese patients. Hepatol Int 7: 233-240, 2013.
17. Cobb WS, Burns JM, Kercher KW, Matthews BD, James Norton H, Todd Heniford B. Normal intraabdominal pressure in healthy adults. J Surg Res 129: 231-235, 2005.
18. Cohen AJ, McCarthy DM, Stoff JS. Direct hemodynamic effect of insulin in the isolated perfused kidney. Am J Physiol Renal Fluid Electrolyte Physiol 257: F580-F585, 1989.
19. Colyer WR, Cooper CJ. Cardiovascular morbidity and mortality and renal artery stenosis. Prog Cardiovasc Dis 52: 238-242, 2009.
20. Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, Reid DM, Cohen DJ, Matsumoto AH, Steffes M, Jaff MR, Prince MR, Lewis EF, Tuttle KR, Shapiro JI, Rundback JH, Massaro JM, D'Agostino RB, Dworkin LD. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 370: 13-22, 2014.
21. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT , Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 4: 393-404, 2002.
22. De Cosmo S, Menzaghi C, Prudente S, Trischitta V. Role of insulin resistance in kidney dysfunction: insights into the mechanism and epide-miological evidence. Nephrol Dial Transplant 28: 29-36, 2013.
23. de Jongh RT, Serne EH, Ijzerman RG, de Vries G, Stehouwer CD. Impaired microvascular function in obesity: implications for obesity-associated microangiopathy, hypertension, and insulin resistance. Circulation 109: 2529-2535, 2004.
24. Dong F, Zhang X, Ren J. Leptin regulates cardiomyocyte contractile function through endothelin-1 receptor-NADPH oxidase pathway. Hypertension 47: 222-229, 2006.
25. Ejerblad E, Fored CM, Lindblad P, Fryzek J, McLaughlin JK, Nyren O. Obesity and risk for chronic renal failure. J Am Soc Nephrol 17: 1695-1702, 2006.
26. Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma AM. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 45: 356-362, 2005.
27. Foster MC, Hwang SJ, Porter SA, Massaro JM, Hoffmann U, Fox CS. Fatty kidney, hypertension, and chronic kidney disease: the Framingham Heart Study. Hypertension 58: 784-790, 2011.
28. Frantz ED, Crespo-Mascarenhas C, Barreto-Vianna AR, Aguila MB, Mandarim-de-Lacerda CA. Renin-angiotensin system blockers protect pancreatic islets against diet-induced obesity and insulin resistance in mice. PLoS One 8: e67192, 2013.
29. Friedman JE, Dohm GL, Elton CW, Rovira A, Chen JJ, Leggett-Frazier N, Atkinson SM , Thomas FT, Long SD, Caro JF. Muscle insulin resistance in uremic humans: glucose transport, glucose transporters, and insulin receptors. Am J Physiol Endocrinol Metab 261: E87-E94, 1991.
30. Fujita T. Aldosterone in salt-sensitive hypertension and metabolic syndrome. J Mol Med (Berl) 86: 729-734, 2008.
31. Goodfriend TL, Egan BM, Kelley DE. Aldosterone in obesity. Endocr Res 24: 789-796, 1998.
32. Gustafsson S, Lind L, Soderberg S, Zilmer M, Hulthe J, Ingelsson E. Oxidative stress and inflammatory markers in relation to circulating levels of adiponectin. Obesity (Silver Spring) 21: 1467-1473, 2013.
33. Hall JE, Brands MW, Dixon WN, Smith MJ . Obesity-induced hypertension. Renal function and systemic hemodynamics. Hypertension 22: 292-299, 1993.
34. Hall ME, do Carmo JM, da Silva AA, Juncos LA, Wang Z, Hall JE. Obesity, hypertension, and chronic kidney disease. Int J Nephrol Renovasc Dis 7: 75-88, 2014.
35. Harada E, Mizuno Y, Katoh D, Kashiwagi Y, Morita S, Nakayama Y, Yoshimura M, Masuzaki H, Saito Y, Yasue H. Increased urinary aldosterone excretion is associated with subcutaneous not visceral, adipose tissue area in obese individuals: a possible manifestation of dysfunctional subcutaneous adipose tissue. Clin Endocrinol (Oxf) 79: 510-516, 2013.
36. Hayashi K, Fujiwara K, Oka K, Nagahama T, Matsuda H, Saruta T. Effects of insulin on rat renal microvessels: studies in the isolated perfused hydronephrotic kidney. Kidney Int 51: 1507-1513, 1997.
37. Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med 144: 21-28, 2006.
38. Ichikawa I, Hoyer , Seiler MW, Brenner BM. Mechanism of glo-merulotubular balance in the setting of heterogeneous glomerular injury. Preservation of a close functional linkage between individual nephrons and surrounding microvasculature. J Clin Invest 69: 185-198, 1982.
39. Iliescu R, Chade AR. Progressive renal vascular proliferation and injury in obese Zucker rats. Microcirculation 17: 250-258, 2010.
40. Iliescu R, Fernandez SR, Kelsen S, Maric C, Chade AR. Role of renal microcirculation in experimental renovascular disease. Nephrol Dial Transplant 25: 1079-1087, 2010.
41. Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 65: 1870-1876, 2004.
42. Jonk AM, Houben AJ, de Jongh RT, Serne EH, Schaper NC, Stehouwer CD. Microvascular dysfunction in obesity: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. Physiology (Bethesda) 22: 252-260, 2007.
43. Kim EY, Anderson M, Dryer SE. Insulin increases surface expression of TRPC6 channels in podocytes: role of NADPH oxidases and reactive oxygen species. Am J Physiol Renal Physiol 302: F298-F307, 2012.
44. Kim EY, Dryer SE. Effects of insulin and high glucose on mobilization of slo1 BKCa channels in podocytes. J Cell Physiol 226: 2307-2315, 2011.
45. Kim W, Moon SO, Lee SY, Jang KY, Cho CH, Koh GY, Choi KS, Yoon KH, Sung MJ, Kim DH, Lee S, Kang KP, Park SK. COMP-angiopoietin-1 ameliorates renal fibrosis in a unilateral ureteral obstruction model. J Am Soc Nephrol 17: 2474-2483, 2006.
46. Kiss E, Kranzlin B, Wagenblabeta K, Bonrouhi M, Thiery J, Grone E, Nordstrom V, Teupser D, Gretz N, Malle E, Grone HJ. Lipid droplet accumulation is associated with an increase in hyperglycemia-induced renal damage: prevention by liver X receptors. Am J Pathol 182: 727-741, 2013.
47. Kong X, Yang , Guo LQ, Xiong Y, Wu XQ, Huang K, Zhou Y. Sesamin improves endothelial dysfunction in renovascular hypertensive rats fed with a high-fat, high-sucrose diet. Eur J Pharmacol 620: 84-89, 2009.
48. Krier JD, Crane JA, Eirin A, Zhu XY, Lerman A, Lerman LO. Hemodynamic determinants of perivascular collateral development in swine renal artery stenosis. Am J Hypertens 26: 209-217, 2013.
49. Kurata A, Nishizawa H, Kihara S, Maeda N, Sonoda M, Okada T, Ohashi K, Hibuse T, Fujita K, Yasui A, Hiuge A, Kumada M, Kuriyama H, Shimomura I, Funahashi T. Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 70: 1717-1724, 2006.
50. Lavi R, Zhu XY, Chade AR, Lin J, Lerman A, Lerman LO. Simva-statin decreases endothelial progenitor cell apoptosis in the kidney of hypertensive hypercholesterolemic pigs. Arterioscler Thromb Vasc Biol 30: 976-983, 2010.
51. Lerman LO, Chade AR. Angiogenesis in the kidney: a new therapeutic target? Curr Opin Nephrol Hypertens 18: 160-165, 2009.
52. Li ZL, Woollard , Ebrahimi B, Crane JA, Jordan KL, Lerman A, Wang SM, Lerman LO. Transition from obesity to metabolic syndrome is associated with altered myocardial autophagy and apoptosis. Arterio-scler Thromb Vasc Biol 32: 1132-1141, 2012.
53. Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML, Wang DJ, Klein AS, Bulkley GB, Bao C, Noble PW, Lane MD, Diehl AM. Leptin regulates proinflammatory immune responses. FASEB J 12: 57-65, 1998.
54. Lohmeier TE, Iliescu R, Liu B, Henegar , Maric-Bilkan C, Irwin ED. Systemic and renal-specific sympathoinhibition in obesity hypertension. Hypertension 59: 331-338, 2012.
55. Lu H, Boustany-Kari CM, Daugherty A, Cassis LA. Angiotensin II increases adipose angiotensinogen expression. Am J Physiol Endocrinol Metab 292: E1280-E1287, 2007.
56. Lu JL, Kalantar-Zadeh K, Ma JZ, Quarles LD, Kovesdy CP. Association of body mass index with outcomes in patients with CKD. JAmSoc Nephrol 25: 2088-2096, 2014.
57. McCaleb ML, Mevorach R, Freeman RB, Izzo MS, Lockwood DH. Induction of insulin resistance in normal adipose tissue by uremic human serum. Kidney Int 25: 416-421, 1984.
58. Mima A, Ohshiro Y, Kitada M, Matsumoto M, Geraldes P, Li C, Li Q, White GS, Cahill C, Rask-Madsen C, King GL. Glomerular-specific protein kinase C-beta-induced insulin receptor substrate-1 dysfunction and insulin resistance in rat models of diabetes and obesity. Kidney Int 79: 883-896, 2011.
59. Nakamura R, Emmanouel DS, Katz AI. Insulin binding sites in various segments of the rabbit nephron. J Clin Invest 72: 388-392, 1983.
60. Namikoshi T, Tomita N, Satoh M, Haruna Y, Kobayashi S, Komai N, Sasaki T, Kashihara N. Pioglitazone enhances the antihypertensive and renoprotective effects of candesartan in Zucker obese rats fed a highprotein diet. Hypertens Res 31: 745-755, 2008.
61. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 311: 806-814, 2014.
62. Ohashi K, Kihara S, Ouchi N, Kumada M, Fujita K, Hiuge A, Hibuse T, Ryo M, Nishizawa H, Maeda N, Maeda K, Shibata R, Walsh K, Funahashi T, Shimomura I. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 47: 1108-1116, 2006.
63. Ott CE, Haas JA, Cuche JL, Knox FG. Effect of increased peritubule protein concentration on proximal tubule reabsorption in the presence and absence of extracellular volume expansion. J Clin Invest 55: 612-620, 1975.
64. Qatanani M, Lazar MA. Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev 21: 1443-1455, 2007.
65. Rutkowski JM, Wang ZV, Park AS, Zhang J, Zhang D, Hu MC, Moe OW, Susztak K, Scherer PE. Adiponectin promotes functional recovery after podocyte ablation. J Am Soc Nephrol 24: 268-282, 2013.
66. Schrijvers BF, Flyvbjerg A, Tilton RG, Lameire NH, De Vriese AS. A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat. Nephrol Dial Transplant 21: 324-329, 2006.
67. Sharma AM. Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension 44: 12-19, 2004.
68. Sharma K, Ramachandrarao S, Qiu G, Usui HK, Zhu Y, Dunn SR, Ouedraogo R, Hough K, McCue P, Chan L, Falkner B, Goldstein BJ. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 118: 1645-1656, 2008.
69. Sieber J, Lindenmeyer MT, Kampe K, Campbell KN, Cohen CD, Hopfer H, Mundel P, Jehle AW. Regulation of podocyte survival and endoplasmic reticulum stress by fatty acids. Am J Physiol Renal Physiol 299: F821-F829, 2010.
70. Sugerman H, Windsor A, Bessos M, Wolfe L. Intra-abdominal pressure, sagittal abdominal diameter and obesity comorbidity. J Intern Med 241: 71-79, 1997.
71. Tejada T, Catanuto P, Ijaz A, Santos JV, Xia X, Sanchez P, Sanabria N, Lenz O, Elliot SJ, Fornoni A. Failure to phosphorylate AKT in podocytes from mice with early diabetic nephropathy promotes cell death. Kidney Int 73: 1385-1393, 2008.
72. Ter Maaten JC, Bakker SJ, Serne EH, Moshage HJ, Donker AJ, Gans RO. Insulin-mediated increases in renal plasma flow are impaired in insulin-resistant normal subjects. Eur J Clin Invest 30: 1090-1098, 2000.
73. Tobar A, Ori Y, Benchetrit S, Milo G, Herman-Edelstein M, Zinger-man B, Lev N, Gafter U, Chagnac A. Proximal tubular hypertrophy and enlarged glomerular and proximal tubular urinary space in obese subjects with proteinuria. PLoS One 8: e75547, 2013.
74. Tobias DK, Pan A, Jackson CL, O'Reilly EJ, Ding EL, Willett WC, Manson JE, Hu FB. Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med 370: 233-244, 2014.
75. Toblli JE, Cao G, DeRosa G, Di Gennaro F, Forcada P. Angiotensin-converting enzyme inhibition and angiogenesis in myocardium of obese Zucker rats. Am J Hypertens 17: 172-180, 2004.
76. Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S. Influence of smoking and obesity on the development of proteinuria. Kidney Int 62: 956-962, 2002.
77. Wahba IM, Mak RH. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol 2: 550-562, 2007.
78. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW . Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112: 1796-1808, 2003.
79. Wisse BE. The inflammatory syndrome: the role of adipose tissue cyto-kines in metabolic disorders linked to obesity. J Am Soc Nephrol 15: 2792-2800, 2004.
80. Xiang L, Dearman J, Abram SR, Carter C, Hester RL. Insulin resistance and impaired functional vasodilation in obese Zucker rats. Am J Physiol Heart Circ Physiol 294: H1658-H1666, 2008.
81. Yamagishi SI, Edelstein D, Du XL, Kaneda Y, Guzman M, Brownlee M. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem 276: 25096-25100, 2001.
82. Yvan-Charvet L, Quignard-Boulange A. Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity. Kidney Int 79: 162-168, 2011.
83. Zhang X, Li ZL, Woollard , Eirin A, Ebrahimi B, Crane JA, Zhu XY, Pawar AS, Krier JD, Jordan KL, Tang H, Textor SC, Lerman A, Lerman LO. Obesity-metabolic derangement preserves hemodynamics but promotes intrarenal adiposity and macrophage infiltration in swine renovascular disease. Am J Physiol Renal Physiol 305: F265-F276, 2013.
84. Zhang X, Urbieta-Caceres VH, Eirin A, Bell CC, Crane JA, Tang H, Jordan KL, Oh YK, Zhu XY, Korsmo MJ, Bachar AR, Cohen P, Lerman A, Lerman LO. Humanin prevents intra-renal microvascular remodeling and inflammation in hypercholesterolemic ApoE deficient mice. Life Sci 91: 199-206, 2012.
85. Zhu XY, Chade AR, Krier JD, Daghini E, Lavi R, Guglielmotti A, Lerman A, Lerman LO. The chemokine monocyte chemoattractant protein-1 contributes to renal dysfunction in swine renovascular hypertension. J Hypertens 27: 2063-2073, 2009.
86. Zorad S, Dou JT, Benicky J, Hutanu D, Tybitanclova K, Zhou J, Saavedra JM. Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adi-ponectin and PPARgamma. Eur J Pharmacol 552: 112-122, 2006.